Content deleted Content added
Citation bot 1 (talk | contribs) m [Pu408]Tweak: issue, title. Formatted dashes. You can use this bot yourself. Report bugs here. |
auto mw |
||
(29 intermediate revisions by 22 users not shown) | |||
Line 1:
{{Short description|Chemical compound}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444674170
| IUPAC_name = 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone
| image = BML-190.
<!--Clinical data-->
Line 25 ⟶ 27:
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 2854-32-2
| ATC_prefix =
Line 35 ⟶ 38:
| chemical_formula =
| C=23 | H=23 | Cl=1 | N=2 | O=4
| smiles = C4COCCN4C(=O)Cc(c(c1cc2)cc2OC)c(C)n1C(=O)c3ccc(Cl)cc3
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 2321
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C23H23ClN2O4/c1-15-19(14-22(27)25-9-11-30-12-10-25)20-13-18(29-2)7-8-21(20)26(15)23(28)16-3-5-17(24)6-4-16/h3-8,13H,9-12,14H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = BJSDNVVWJYDOLK-UHFFFAOYSA-N
}}
'''BML-190''' ('''Indomethacin morpholinylamide''') is a drug used in scientific research
== References ==
{{Reflist}}
Line 47 ⟶ 55:
[[Category:Cannabinoids]]
[[Category:
[[Category:
[[Category:
[[Category:
[[Category:Tryptamines]]
|
Latest revision as of 07:48, 25 March 2024
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H23ClN2O4 |
Molar mass | 426.90 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
BML-190 (Indomethacin morpholinylamide) is a drug used in scientific research that acts as a selective CB2 inverse agonist.[1] BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity.[2] The activity produced by this compound is disputed, with some sources referring to it as a CB2 agonist rather than an inverse agonist;[3][4] this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.
References[edit]
- ^ New DC, Wong YH (February 2003). "BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates". FEBS Letters. 536 (1–3): 157–60. doi:10.1016/S0014-5793(03)00048-6. PMID 12586356. S2CID 38569901.
- ^ Klegeris A, Bissonnette CJ, McGeer PL (June 2003). "Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor". British Journal of Pharmacology. 139 (4): 775–86. doi:10.1038/sj.bjp.0705304. PMC 1573900. PMID 12813001.
- ^ Melck D, De Petrocellis L, Orlando P, Bisogno T, Laezza C, Bifulco M, Di Marzo V (January 2000). "Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation". Endocrinology. 141 (1): 118–26. doi:10.1210/endo.141.1.7239. PMID 10614630.
- ^ Scutt A, Williamson EM (January 2007). "Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors". Calcified Tissue International. 80 (1): 50–9. doi:10.1007/s00223-006-0171-7. PMID 17205329. S2CID 23624771.